A new trading day began on Friday, with Akebia Therapeutics Inc (NASDAQ: AKBA) stock price down -2.47% from the previous day of trading, before settling in for the closing price of $3.65. AKBA’s price has ranged from $0.80 to $4.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -13.72% over the past five years. Meanwhile, its annual earnings per share averaged 80.61%. With a float of $251.57 million, this company’s outstanding shares have now reached $261.64 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is 67.77%, operating margin of -11.91%, and the pretax margin is -24.51%.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Akebia Therapeutics Inc is 4.10%, while institutional ownership is 36.53%. The most recent insider transaction that took place on Jun 09 ’25, was worth 60,150. In this transaction SVP, Chief Accounting Officer of this company sold 15,000 shares at a rate of $4.01, taking the stock ownership to the 266,914 shares. Before that another transaction happened on Jun 04 ’25, when Company’s SVP, Chief Accounting Officer sold 13,334 for $3.53, making the entire transaction worth $47,069. This insider now owns 266,914 shares in total.
Akebia Therapeutics Inc (AKBA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 80.61% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Here are Akebia Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.07 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics Inc (NASDAQ: AKBA) saw its 5-day average volume 7.36 million, a positive change from its year-to-date volume of 4.24 million. As of the previous 9 days, the stock’s Stochastic %D was 51.83%. Additionally, its Average True Range was 0.23.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 79.82%, which indicates a significant increase from 57.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.06% in the past 14 days, which was lower than the 94.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.60, while its 200-day Moving Average is $2.01. Nevertheless, the first resistance level for the watch stands at $3.67 in the near term. At $3.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.86. If the price goes on to break the first support level at $3.48, it is likely to go to the next support level at $3.40. The third support level lies at $3.29 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
With a market capitalization of 934.98 million, the company has a total of 262,636K Shares Outstanding. Currently, annual sales are 160,180 K while annual income is -69,410 K. The company’s previous quarter sales were 57,340 K while its latest quarter income was 6,110 K.
